Autoreactive T Cells in Healthy Individuals1

The presence of autoreactive CD4+ T cells in the peripheral blood of healthy human subjects was investigated after removal of CD4+CD25+ regulatory T cells (Treg). CD4+ T cells that were directed against the type 1 diabetes-associated autoantigen glutamic acid decarboxylase 65, the melanocyte differentiation Ag tyrosinase, and the cancer/testis tumor Ag NY-ESO-1 were readily derived from PBMC of healthy individuals. These autoreactive T cells could be visualized, using Ag-specific class II tetramer reagents, in the peripheral blood of most individuals examined. Addition of CD4+CD25+ Treg back to the CD4+CD25− population suppressed the expansion of the autoreactive T cells. Autoreactive T cells were cloned based on tetramer binding, and expressed characteristic activation markers upon self-Ag stimulation. These results show that autoreactive T cells are present in most healthy individuals and that Treg likely play an important role of keeping these autoreactive T cells in check.

[1]  Hiroya Kobayashi,et al.  Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient , 1998, Immunogenetics.

[2]  Andrew W. Liu,et al.  MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. , 1999, The Journal of clinical investigation.

[3]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[4]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[5]  F. Powrie,et al.  Cutting Edge: Cure of Colitis by CD4+CD25+ Regulatory T Cells1 , 2003, The Journal of Immunology.

[6]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[7]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[8]  J. Bijlsma,et al.  Antigen‐specific T cell suppression by human CD4+CD25+ regulatory T cells , 2002, European journal of immunology.

[9]  P. Marrack,et al.  Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[11]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[12]  E. Appella,et al.  p53110–124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells , 2003 .

[13]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[14]  E. Appella,et al.  P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. , 2003, Cancer research.

[15]  Andrew W. Liu,et al.  Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. , 2002, Diabetes.

[16]  C. Fathman,et al.  The Subpopulation of CD4+CD25+ Splenocytes That Delays Adoptive Transfer of Diabetes Expresses L-Selectin and High Levels of CCR71 , 2002, The Journal of Immunology.

[17]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[18]  F. Powrie,et al.  Regulatory T cells and inflammatory bowel disease. , 1999, Immunology today.

[19]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[20]  H. Reijonen,et al.  Low‐avidity recognition by CD4+ T cells directed to self‐antigens , 2003, European journal of immunology.

[21]  Simon J Davis,et al.  Molecular interactions mediating T cell antigen recognition. , 2003, Annual review of immunology.

[22]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Wood,et al.  Regulatory lymphocytes: Regulatory T cells in transplantation tolerance , 2003, Nature Reviews Immunology.

[24]  H. Waldmann,et al.  Regulatory T cells in transplantation tolerance. , 2005, Current topics in microbiology and immunology.

[25]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[26]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[27]  S. Lundin,et al.  CD4 T cell activation by myelin oligodendrocyte glycoprotein is suppressed by adult but not cord blood CD25+ T cells , 2003, European journal of immunology.

[28]  W. Kwok,et al.  Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis. , 2002, Arthritis and rheumatism.

[29]  Hugh Auchincloss,et al.  Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. , 2002, Immunity.

[30]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[31]  V. Cerundolo,et al.  The use of HLA class I tetramers to design a vaccination strategy for melanoma patients , 2002, Immunological reviews.